Brief: Syncona Reports Positive Phase II Dawn Trial Results From Beacon Therapeutics
07/05/2025 07:34
May 7 (Reuters) - Syncona Ltd SYNCS.L: SYNCONA LTD - BEACON THERAPEUTICS ANNOUNCES POSITIVE PHASE II DAWN TRIAL RESULTS Source text: ID:nRSG5357Ha Further company coverage: SYNCS.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syncona
See all newsBrief: Syncona Reports Net Assets Of £1.07 Billion, Nav Per Share Of 175.7p, 3.0% Return For Six Months Ended Sept 30, 2026
Syncona Limited - Half-year Report
Syncona Limited - Holding(s) in Company
Brief: Syncona Commits $10.10 Million To OMass $310 Million Series C Financing
Syncona Limited - OMass raises $310 million in Series C financing